Richard Chen, PA
Staff Affiliate in Emergency MedicineAbout
Research
Publications
2024
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.
Waks A, Tarantino P, Li T, Ogayo E, Rahman T, DiLullo M, El-Refai S, Abbott C, Boyle S, Chen R, Desai N, Spring L, Tung N, King T, Krop I, Tayob N, Mittendorf E, Tolaney S, Winer E, Parsons H. Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial. Journal Of Clinical Oncology 2024, 42: 588-588. DOI: 10.1200/jco.2024.42.16_suppl.588.Peer-Reviewed Original ResearchMinimal residual diseaseResidual cancer burdenBreast cancerResidual diseaseDynamics of circulating tumor DNAMinimal residual disease dataRCB 0RCB IIResidual cancer burden-IDetect minimal residual diseaseQuantify minimal residual diseaseResidual cancer burden scoreHER2+ breast cancerAdjuvant systemic therapyClinical stage IINode-negative tumorsHER2 + BCMedian follow-upPlasma samplesBreast cancer recurrenceImmediately post-operativelyLong-term outcomesAssociated with elevated riskCtDNA-positiveT3/T4 tumorsCirculating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNARecurrence-free survivalColorectal cancerMRD assaysDetection of molecular residual diseaseLevels of circulating tumor DNAPoor recurrence-free survivalTreated with curative intentDetect circulating tumor DNAProspective cohort of patientsCurative interventionsCurative-intent treatmentCohort of patientsSingle nucleotide variantsStage I-IIISeparation of patientsMRD- patientsMRD testingNeoadjuvant treatmentResidual diseaseClinical recurrenceCurative intentRectal cancerTumor DNAUltra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Garcia-Murillas I, Cutts R, Abbott C, Boyle S, Pugh J, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. Journal Of Clinical Oncology 2024, 42: 1010-1010. DOI: 10.1200/jco.2024.42.16_suppl.1010.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAEarly breast cancerBreast cancer patientsFollow-upNeoadjuvant chemotherapyResidual diseaseClinical relapseCtDNA detectionClinical outcomesBreast cancerAssociated with relapse free survivalDetection of molecular residual diseaseCancer patientsCirculating tumor DNA levelsLevels of circulating tumor DNAHigh risk of relapseHigh riskCirculating tumor DNA detectionMedian lead-timeRelapse free survivalDe-escalation studiesBreast cancer relapseShortened overall survivalBaseline prior to treatmentPrognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
Toledo R, Calahorro García A, Mirallas O, Moreno A, Galvao V, Alonso G, Vieito M, Brana I, Oberoi A, Lostes-Bardaji M, Jimenez J, Sanz M, Viaplana C, Perez-Lopez R, Nuciforo P, Abbott C, Pugh J, Chen R, Boyle S, Garralda E. Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. Journal Of Clinical Oncology 2024, 42: 2510-2510. DOI: 10.1200/jco.2024.42.16_suppl.2510.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPhase 1 clinical trialMolecular residual diseaseCheckpoint inhibitorsCtDNA levelsICI responseDetection of molecular residual diseaseDynamics of circulating tumor DNATreated with immune checkpoint inhibitorsDuration of PFSRefractory metastatic tumorsImmune checkpoint inhibitionAccurate patient managementLiquid biopsy testingTreatment cycle 3Levels of ctDNAStage IV cancer patientsLiquid biopsy platformPan-cancer cohortAssociated with significant increasesSequencing of tumorsWhole-genome sequencing of tumoursCtDNA clearanceCtDNA dynamicsCtDNA monitoringUltra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
Nixon A, Navarro F, Zhou K, Abbott C, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Chen R, Strickler J, Boyle S, Uronis H. Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer. Journal Of Clinical Oncology 2024, 42: 4025-4025. DOI: 10.1200/jco.2024.42.16_suppl.4025.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerMolecular residual diseaseImmune checkpoint blockadeProgression-free survivalCtDNA dynamicsCtDNA levelsHigher hazard ratioOverall survivalDetection of molecular residual diseasePhase II study of pembrolizumabSingle-arm phase II studyWhole-genome sequencingSingle nucleotide variantsMolecular progressionResponse rateStudy of pembrolizumabBaseline prior to treatmentUnivariate Cox regression analysisCox regression analysisFFPE tumor samplesOverall response rateMedian lead timeImprove treatment decision-makingLong-term survivalLiquid biopsy platformAn algorithm to identify patients aged 0–3 with rare genetic disorders
Webb B, Lau L, Tsevdos D, Shewcraft R, Corrigan D, Shi L, Lee S, Tyler J, Li S, Wang Z, Stolovitzky G, Edelmann L, Chen R, Schadt E, Li L. An algorithm to identify patients aged 0–3 with rare genetic disorders. Orphanet Journal Of Rare Diseases 2024, 19: 183. PMID: 38698482, PMCID: PMC11064409, DOI: 10.1186/s13023-024-03188-9.Peer-Reviewed Original ResearchConceptsAged 0Electronic medical record dataIncreased riskMedical record dataMedical diagnosis codesChart reviewElectronic medical recordsChildren aged 0Diagnostic genetic testingGenetic disordersAlerting providersPatients aged 0Medical geneticistsPhenotyping algorithmsDiagnosis codesRecord dataGenetic testingMedical recordsLive birthsDisorder diagnosisRare genetic disordersIncompleteness of recordsMendelian disordersClinical symptomsExpert opinion
2023
LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer
Black J, Frankell A, Veeriah S, Colopi M, Hill M, Abbott C, Boyle S, Li B, Chen R, Al Bakir M, Ruiz C, Huebner A, Jamal-Hanjani M, McGranahan N, Swanton C. LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Annals Of Oncology 2023, 34: s1294. DOI: 10.1016/j.annonc.2023.10.049.Peer-Reviewed Original Research
2022
119 Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma
Li B, Abbott C, McDaniel L, Pyke R, Navarro F, Anbunathan H, Synder M, Jang S, Boyle S, Chen R. 119 Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma. 2022, a131-a131. DOI: 10.1136/jitc-2022-sitc2022.0119.Peer-Reviewed Original Research692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Perales R, Perales-Puchalt A, Bartha G, Northcott J, Chen R, Lyle J, Norton D, Cooch N, Gane E, Yarchoan M, Marron T, Rochestie S, Peters J, Csiki I, Yan J, Sardesai N. 692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab). 2022, a723-a723. DOI: 10.1136/jitc-2022-sitc2022.0692.Peer-Reviewed Original Research
2021
P35.09 Oncogenetic Differences in Never-Smokers versus Smokers with NSCLC Adenocarcinoma Treated at the Mt Sinai Tisch Cancer Institute
Klein M, Mack P, Guin S, Gong Y, O'Connell T, Ayers K, Li Z, Li Y, Mullaney T, Jappe W, Redfern A, Prentice T, Schadt E, Fink M, Zhou X, Newman S, Chen R, Hirsch F. P35.09 Oncogenetic Differences in Never-Smokers versus Smokers with NSCLC Adenocarcinoma Treated at the Mt Sinai Tisch Cancer Institute. Journal Of Thoracic Oncology 2021, 16: s423. DOI: 10.1016/j.jtho.2021.01.710.Peer-Reviewed Original Research